Regenesome Inc. Launches New Longevity Lab at Takanawa Gateway City

Regenesome Inc., a subsidiary of Space Seed Holdings based in Minato, Tokyo, has officially opened its new headquarters and research facility, the "Takanawa Longevity Lab," at the innovative hub known as LiSH in Takanawa Gateway City. Set to begin operations on May 13, 2025, the lab will serve as a center for cutting-edge research into biotechnology related to aging, prototyping, and commercialization initiatives.

Background and Objective

The mission of Regenesome is to develop anti-aging technologies that can be applied not only for human habitation on the moon by 2040 but also beneficially on Earth. The company has been actively researching nanoscale particles, including exosomes and gene therapy technologies, aimed at revolutionizing healthcare.
The LiSH facility, operated by East Japan Railway Company, supports startups by fostering collaborations with research institutions and facilitating practical experimental environments. Within this setting, Regenesome will focus on several key research themes.

Initiatives at the Takanawa Longevity Lab

1. Collaborative Research with Tohoku University

Regenesome will begin joint research leveraging equipment installed at LiSH. The focus will be on examining the reversibility of aging from various biological markers and epigenetic perspectives. This collaboration underscores the importance of academic partnerships in advancing scientific understanding.

2. Development of Gene-Related Technologies to Combat Aging

Working with companies like Good Hero Therapeutics, which has been recognized by the Agency for Medical Research and Development (AMED), Regenesome is progressing in the joint development of virus vectors aimed at rejuvenation. The future may see applications of drug delivery systems based on nanoscale particles and liposomes.

3. Creation of New Healthcare Products

The lab is also concentrating on developing healthcare products utilizing functional components found in sake, termed "SAKESOME." The first product is expected to launch between May and June 2025. Ongoing research will explore combinations with anti-aging materials and innovative new product developments using the latest technologies.

Future Prospects

The Takanawa Longevity Lab is envisioned as a comprehensive center for contracted research, practical experiments, and product development. Regenesome aims to strengthen collaborations with academic institutions like Tohoku University to enhance societal implementations of services that evaluate exosome measurements.

About Regenesome Inc.

With a focus on leveraging nanoscale particles such as exosomes, Regenesome is dedicated to providing new solutions for aging suppression and regenerative medicine. By dissecting the intricate functions of exosomes generated by various cells and designing nanoparticles at the molecular biological level, the company aims to develop medical technologies that not only enhance health spans but also propose new solutions for space medicine, thereby contributing to humanity's advancement into space. More information can be found at Regenesome.com.

About Space Seed Holdings

Space Seed Holdings operates as a deep tech venture builder with the mission of "turning science fiction into non-fiction." The company is involved in investment activities, research, and the creation of enterprises aimed at supporting the social implementation of fermentation and longevity technologies. Through initiatives like its Fermentation and Longevity Fund program, it addresses social issues by creating businesses intended to equip humanity with the necessary technologies for habitation in outer space by 2040. Learn more at SS-HD.co.jp.